Broken String adds a base-editing off-target assay
The BaseMap ABE launch offers genome-wide measurements in relevant cells to support off-target characterisation during therapeutic development. The reported capability is a product or workflow announcement, not independent proof of clinical diagnostic performance.
- Published by
- GEN — Genetic Engineering & Biotechnology News
- Evidence type
- Industry
GEN reports: The BaseMap ABE launch offers genome-wide measurements in relevant cells to support off-target characterisation during therapeutic development.
The reported capability is a product or workflow announcement, not independent proof of clinical diagnostic performance. Consult the linked GEN report for the source organisation’s full announcement.
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through GMP supply.
Prefer to talk it through? Book a 30-minute discovery call